MedTrace Logo

Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden

NCT04708626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2022-11-09

No results posted yet for this study

Summary

Autoimmune encephalitis and paraneoplastic neurological syndromes are rare diseases caused by an abnormal immune response toward the nervous system. This can lead to life-threatening symptoms, but is in many cases treatable if a swift and correct diagnosis is made. Antibodies targeting neuronal proteins (i.e. "neuronal antibodies") can be detected in serum or cerebrospinal fluid (CSF) in about half of the patients suffering from these conditions. Although an important part of the diagnostical process of these conditions, diagnosis cannot be made only based on a positive antibody test, but the clinical findings have to be compatible as well. As these conditions are so rare, clinicians might struggle to interpret antibody test results.

In this study the investigators aim to estimate the incidence rate of autoimmune encephalitides and paraneoplastic neurological syndromes in the Uppsala-Örebro health care region in Sweden between the years 2015 and 2019. Medical records from patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or CSF will be studied to obtain clinical, laboratory and radiological data. This data will be used to ascertain if diagnostic criteria are fulfilled as well as to describe clinical characteristics and identifying possible comorbidities.

Conditions

  • Autoimmune Encephalitis
  • Paraneoplastic Neurological Syndrome

Interventions

OTHER

Description and analysis

Collection of clinical, laboratory and radiological data from medical records.

OTHER

Description and analysis

Collection of laboratory data.

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Joachim Burman, Assoc prof · Uppsala University

  • Anna Rostedt Punga, Professor · Uppsala University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708626 on ClinicalTrials.gov